Search results
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Our community are the reason we are able to continue supporting those with inherited sight-loss conditions through research and practical support.
These are some of the most commonly asked questions about volunteering for our charity.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Take on a challenge with #TeamRetinaUK! Run, jog or walk 10 miles in your neighbourhood.
